Association of human leukocyte antigen (HLA) status with immune checkpoint inhibitor (ICI) pneumonitis in patients with non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Li, Molly S. C.
Cheung, Alvin H. K.
Mui, Zeta
Chow, Chit
Lau, Yat Ming
Wong, Kit Yee
Kang, Wei
To, Ka Fai
Mok, Tony S. K.
机构：
[1] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China
[3] Prince Wales Hosp, Hong Kong, Peoples R China
[4] Chinese Univ Hong Kong, Dept Cellular & Anat Pathol, Hong Kong, Peoples R China
[5] Chinese Univ Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8620
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).
    Stuart, Jessica
    Ricciuti, Biagio
    Alessi, Joao Victor Machado
    Nishino, Mizuki
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] HLA-A2 Status and Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Mezquita, Laura
    Charrier, Melinda
    Auclin, Edouard
    Dupraz, Louise
    Remon, Jordi
    Planchard, David
    Gion, Maria
    Lahmar, Jihene
    Gazzah, Annas
    Adam, Julien
    Chaput, Nathalie
    Besse, Benjamin
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1316 - S1316
  • [3] The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
    Xiaoyang Zhai
    Jian Zhang
    Yaru Tian
    Ji Li
    Wang Jing
    Hongbo Guo
    Hui Zhu
    Cancer Biology & Medicine, 2020, 17 (03) : 599 - 611
  • [4] The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
    Zhai, Xiaoyang
    Zhang, Jian
    Tian, Yaru
    Li, Ji
    Jing, Wang
    Guo, Hongbo
    Zhu, Hui
    CANCER BIOLOGY & MEDICINE, 2020, 17 (03) : 599 - 611
  • [5] The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
    Xiaoyang Zhai
    Jian Zhang
    Yaru Tian
    Ji Li
    Wang Jing
    Hongbo Guo
    Hui Zhu
    Cancer Biology & Medicine, 2020, (03) : 599 - 611
  • [6] Response to neoadjuvant immune checkpoint inhibitor (ICI)-based therapy in oncogenedriven resectable non-small cell lung cancer (NSCLC)
    Rosner, Samuel
    Sivapalan, Lavanya
    Zahurak, Marianna
    Thummalapalli, Rohit
    Rayes, Roni
    Connor, Sydney
    Sanber, Khaled
    Reuss, Joshua E.
    Pereira, Gavin
    Smith, Kellie Nicole
    Anagnostou, Valsamo
    Broderick, Stephen
    Jones, David Randolph
    Brahmer, Julie R.
    Marrone, Kristen A.
    Spicer, Jonathan
    Chaft, Jamie E.
    Forde, Patrick M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC)
    Lee, Seyoung
    Hiremath, Amogh
    Lee, Jeeyeon
    Kim, Haseok
    Zhang, Kai
    Lee, Salie
    Yadav, Monica
    Chung, Liam Il Young
    Kim, Hye Sung
    Djunadi, Trie Arni
    Kim, Yuchan
    Hong, Ilene
    Kang, Grace
    Cho, Amy
    Velichko, Yury
    Gupta, Amit
    Velcheti, Vamsidhar
    Madabhushi, Anant
    Braman, Nathaniel
    Chae, Young Kwang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Immunotherapy Fits Everyone? Prognostic Markers for Immune-checkpoint-Inhibitor (ICI) in Non-small Cell Lung Cancer (NSCLC)
    Baptista De Almeida, S.
    Caleca, T.
    Silva, M.
    Honorio, M.
    Chaves, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1136 - S1136
  • [9] Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review
    Hao, Yuxuan
    Zhang, Xiaoye
    Yu, Li
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Prognostic impact of KRAS status in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitor monotherapy
    Pelizzari, G.
    Corvaja, C.
    Targato, G.
    Buriolla, S.
    Bortolot, M.
    Torresan, S.
    Fantin, A.
    De Maglio, G.
    Rossetto, C.
    Rizzato, S.
    Fasola, G.
    Follador, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1011 - S1011
12345